- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
ICC Labs Signs Agreement to Export Medical Cannabis to Germany
ICC Labs signed a letter of intent with CanPharma GmbH to export cannabidiol (CBD) and tetrahydrocannabinol (THC) medical products.
ICC Labs (TSXV:ICC) signed a letter of intent with CanPharma GmbH to export cannabidiol (CBD) and tetrahydrocannabinol (THC) medical products to Germany.
As quoted in the press release:
Through its relationship with CanPharma, ICC Labs intends to export to Germany cannabidiol (CBD) isolate, oils and other derivatives, as well as various medicinal tetrahydrocannabinol (THC) cannabis products, including dried flowers and cannabis extracts from our facilities in Uruguay and Colombia. The export arrangement for (THC) cannabis products is subject to receipt of the requisite regulatory approvals and the negotiation of definitive agreements by the end of second quarter in 2018.
“As part of our strategy to gain a foothold in the European markets, we expect that CanPharma would distribute imported “BIDIOL” branded CBD oils and other medicinal CBD derivatives through German pharmacies. Our CO2 extraction laboratory currently under construction in Uruguay’s Science Park free trade zone in accordance with international Good Manufacturing Practices (GMP) guidelines is expected allow us to meet all the GMP requirements from the German regulatory authorities.
Click here to read the full press release.
Source: globenewswire.com
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.